Factors Regulating the Function and Assembly of the Sarcoglycan Complex in Brain

Total Page:16

File Type:pdf, Size:1020Kb

Factors Regulating the Function and Assembly of the Sarcoglycan Complex in Brain Factors regulating the function and assembly of the sarcoglycan complex in brain A thesis submitted for the Degree of Doctor of Philosophy at Cardiff University School of Medicine Francesca Carlisle 2016 Supervised by Professor Derek Blake and Professor Anthony Isles Thesis summary Myoclonus dystonia (MD) is a neurogenic movement disorder that can be caused by mutations in the SGCE gene encoding ε-sarcoglycan. ε-sarcoglycan belongs to the sarcoglycan family of cell surface-localised, single-pass transmembrane proteins originally identified in muscle where they form a heterotetrameric subcomplex of the dystrophin- associated glycoprotein complex (DGC). Mutations in the SGCA, SGCB, SGCG and SGCD genes encoding α-, β-, γ- and δ-sarcoglycan cause limb-girdle muscular dystrophy (LGMD). There is no phenotypic overlap between MD and LGMD. LGMD-associated sarcoglycan mutations impair trafficking of the entire sarcoglycan complex to the cell surface and destabilise the DGC in muscle, while MD-associated mutations typically result in loss of ε- sarcoglycan from the cell surface. This suggests cell surface ε-sarcoglycan but not other sarcoglycans is required for normal brain function. To gain insight into ε-sarcoglycan’s function(s) in the brain, immunoaffinity purification was used to identify ε-sarcoglycan- interacting proteins. Ubiquitous and brain-specific ε-sarcoglycan isoforms co-purified with three other sarcoglycans including ζ-sarcoglycan (encoded by SGCZ) from the brain. Incorporation of an LGMD-associated β-sarcoglycan mutant into the brain sarcoglycan complex impaired the formation of the βδ-sarcoglycan core but failed to abrogate the association and trafficking of ε- and ζ-sarcoglycan in heterologous cells. Both ε-sarcoglycan isoforms also co-purified with β-dystroglycan, indicating inclusion in DGC-like complexes. Additionally, the brain-specific ε-sarcoglycan isoform co-purified with the perineuronal net component tenascin-R, potentially suggesting a unique function for this isoform in modulating synapses. In common with SGCE, transcripts from the genes encoding α-, β-, δ-, γ- and ζ-sarcoglycans were found to undergo extensive alternative splicing, in some cases producing novel isoforms that affected assembly and trafficking of the sarcoglycan complex. In summary, data presented herein show that alternatively spliced sarcoglycan isoforms are part of the DGC in brain. These data contribute to our understanding of MD pathophysiology and the role of the sarcoglycan protein family. [i] Declarations This work has not been submitted in substance for any other degree or award at this or any other university or place of learning, nor is being submitted concurrently in candidature for any degree or other award. Signed: Date: 20.09.2016 STATEMENT 1 This thesis is being submitted in partial fulfilment of the requirements for the degree of PhD. Signed: Date: 20.09.2016 STATEMENT 2 This thesis is the result of my own independent work/investigation, except where otherwise stated. Other sources are acknowledged by explicit references. The views expressed are my own. Signed: Date: 20.09.2016 STATEMENT 3 I hereby give consent for my thesis, if accepted, to be available online in the University’s Open Access repository and for inter-library loan, and for the title and summary to be made available to outside organisations. Signed Date: 20.09.2016 STATEMENT 4 I hereby give consent for my thesis, if accepted, to be available online in the University’s Open Access repository and for inter-library loans after expiry of a bar on access previously approved by the Academic Standards & Quality Committee. Signed: No bar on access required. Date: 20.09.2016 [ii] Acknowledgements Firstly, I would like to thank my supervisors Professor Derek Blake and Professor Anthony Isles for giving me the opportunity to work on this project. It has been a fascinating and challenging experience. I am immensely grateful to all those who have helped me out in the lab with training, advice, cheer, commiserations and desperate begging for just a tiny bit of this one reagent. In particular, I would like to thank Adrian for his endless advice, support, and willingness to share his ridiculously impressive knowledge of biochemistry. Other stars of the last three years include Alis, Matt, Taniesha, Anna, the other Anna, Lesley, Alex, Magda and Kira. Their help got me through many a trying day. Eloise, Jenny and Sarah – thank you from the bottom of my heart for the coffee dates, bake off hysteria, science jokes and everything else. You helped me keep it together when things got dark, and celebrated with me when things went well. Thank you also to my many friends at Ceroc South Wales, for the silliness and fun we had at each class. Without your good cheer and friendship, I would probably be irredeemably insane by now. To my fellow Aslam House princesses, Alison, Hannah, Stacy and Laura: we made it!!! Last but definitely not least, to my family: Mum, Dad, Emily, Charlie, Grandma, Sally, and my innumerable extended family – I cannot properly express how grateful I am to you for the support, encouragement and love. Even when I thought I couldn’t do it, you did. Thank you. [iii] Abbreviations dATP 2’-deoxyadenosine 5’-triphosphate dCTP 2’-deoxycytidine 5’-triphosphate dGTP 2’-deoxyguanosine 5’-triphosphate dNTP 2’-deoxynucleoside 5’-triphosphate dTTP 2’-deoxythymidine 5’-triphosphate ADom autosomal dominant AR autosomal recessive ATP adenosine triphosphate AP affinity purification α-SG alpha sarcoglycan aa amino acid N-terminus amino-terminus APS ammonium persulfate Amp ampicillin bp base pair BLAST basic local alignment search tool β-SG beta sarcoglycan BLAT BLAST-like alignment tool BSA bovine serum albumin CIP calf intestinal alkaline phosphatase CO2 carbon dioxide C-terminus carboxyl-terminus CNS central nervous system cDNA complementary DNA °C degrees Celsius δ-SG delta sarcoglycan DNA deoxyribonucleic acid DMP dimethylpimelimidate dihydrochloride DMSO dimethylsulphoxide DRD dopamine-responsive dystonia DTT dithiothreitol DMD Duchenne muscular dystrophy DMEM Dulbeccos modified Eagle medium DGC dystrophin-associated glycoprotein complex ER endoplasmic reticulum ERAD endoplasmic reticulum-associated degradation ε-SG epsilon sarcoglycan EDTA ethylenediaminetetraacetic acid EGTA ethyleneglycoltetraacetic acid ECACC European Collection of Authenticated Cell Cultures EST expressed sequence tag ECM extracellular matrix FBS foetal bovine serum fMRI functional magnetic resonance imaging γ-SG gamma sarcoglycan GST glutathione-S-transferase g gram [iv] HA human influenza haemagglutinin Tris-HCl HCl-buffered tris(hydroxymethyl)aminomethane h hour HEK human embryonic kidney IAP immunoaffinity purification IgG immunoglobulin G IP immunoprecipitation kb kilobase kDa kilodalton LGMD limb-girdle muscular dystrophy l litre LB Luria-Bertani media MRI magnetic resonance imaging mRNA messenger ribonucleic acid miRNA micro ribonucleic acid µg microgram µl microliter µM micromolar ml millilitre mM millimolar min minute M molar MD myoclonus dystonia TEMED N,N,N’,N’-tetramethylethylenediamine ng nanogram nM nanomolar NCBI National Centre for Biotechnology Information NE nuclear envelope nt nucleotide OD optical density PNN perineuronal net PBS phosphate-buffered saline PAGE polyacrylamide gel electrophoresis PCR polymerase chain reaction PET positron emission tomography PTC premature termination codon pre-mRNA pre-messenger ribonucleic acid RIPA radioimmunoprecipitation assay RT-PCR reverse transcriptase polymerase chain reaction rpm revolutions per minute RNA ribonucleic acid SG sarcoglycan SGC sarcoglycan complex s second SDS sodium dodecyl sulphate SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis SEM standard error of the mean Tet tetracycline Thx thioredoxin TMS transcranial magnetic stimulation [v] Tris tris(hydroxymethyl)aminomethane TBST tris-buffered saline-Tween-20 U units UTR untranslated region v/v volume to volume ratio w/v weight to volume ratio Zeo zeocin ζ-SG zeta sarcoglycan β-me β-mercaptoethanol [vi] Table of contents Thesis summary .......................................................................................................................... i Declarations ............................................................................................................................... ii Acknowledgements .................................................................................................................. iii Abbreviations ............................................................................................................................ iv Table of contents ...................................................................................................................... vii List of figures and tables ........................................................................................................... xi Chapter 1: General introduction ............................................................................................ 1 1.1. Introduction ..................................................................................................................... 1 1.2. Overview of dystonia ...................................................................................................... 1 1.2.1. Classification of dystonia ........................................................................................ 2 1.2.1.1. Axis I: clinical features ...................................................................................
Recommended publications
  • Cover Petra B
    UvA-DARE (Digital Academic Repository) The role of Polycomb group proteins throughout development : f(l)avoring repression van der Stoop, P.M. Link to publication Citation for published version (APA): van der Stoop, P. M. (2009). The role of Polycomb group proteins throughout development : f(l)avoring repression. Amsterdam: Nederlands Kanker Instituut - Antoni Van Leeuwenhoekziekenhuis. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl) Download date: 27 Oct 2019 Chapter 4 Ubiquitin E3 Ligase Ring1b/Rnf2 of Polycomb Repressive Complex 1 Contributes to Stable Maintenance of Mouse Embryonic Stem Cells Petra van der Stoop*, Erwin A. Boutsma*, Danielle Hulsman, Sonja Noback, Mike Heimerikx, Ron M. Kerkhoven, J. Willem Voncken, Lodewyk F.A. Wessels, Maarten van Lohuizen * These authors contributed equally to this work Adapted from: PLoS ONE (2008) 3(5): e2235 Ring1b regulates ES cell fate Ubiquitin E3 Ligase Ring1b/Rnf2 of Polycomb Repressive Complex 1 Contributes to Stable Maintenance of Mouse Embryonic Stem Cells Petra van der Stoop1*, Erwin A.
    [Show full text]
  • Supplementary Table 3 Complete List of RNA-Sequencing Analysis of Gene Expression Changed by ≥ Tenfold Between Xenograft and Cells Cultured in 10%O2
    Supplementary Table 3 Complete list of RNA-Sequencing analysis of gene expression changed by ≥ tenfold between xenograft and cells cultured in 10%O2 Expr Log2 Ratio Symbol Entrez Gene Name (culture/xenograft) -7.182 PGM5 phosphoglucomutase 5 -6.883 GPBAR1 G protein-coupled bile acid receptor 1 -6.683 CPVL carboxypeptidase, vitellogenic like -6.398 MTMR9LP myotubularin related protein 9-like, pseudogene -6.131 SCN7A sodium voltage-gated channel alpha subunit 7 -6.115 POPDC2 popeye domain containing 2 -6.014 LGI1 leucine rich glioma inactivated 1 -5.86 SCN1A sodium voltage-gated channel alpha subunit 1 -5.713 C6 complement C6 -5.365 ANGPTL1 angiopoietin like 1 -5.327 TNN tenascin N -5.228 DHRS2 dehydrogenase/reductase 2 leucine rich repeat and fibronectin type III domain -5.115 LRFN2 containing 2 -5.076 FOXO6 forkhead box O6 -5.035 ETNPPL ethanolamine-phosphate phospho-lyase -4.993 MYO15A myosin XVA -4.972 IGF1 insulin like growth factor 1 -4.956 DLG2 discs large MAGUK scaffold protein 2 -4.86 SCML4 sex comb on midleg like 4 (Drosophila) Src homology 2 domain containing transforming -4.816 SHD protein D -4.764 PLP1 proteolipid protein 1 -4.764 TSPAN32 tetraspanin 32 -4.713 N4BP3 NEDD4 binding protein 3 -4.705 MYOC myocilin -4.646 CLEC3B C-type lectin domain family 3 member B -4.646 C7 complement C7 -4.62 TGM2 transglutaminase 2 -4.562 COL9A1 collagen type IX alpha 1 chain -4.55 SOSTDC1 sclerostin domain containing 1 -4.55 OGN osteoglycin -4.505 DAPL1 death associated protein like 1 -4.491 C10orf105 chromosome 10 open reading frame 105 -4.491
    [Show full text]
  • 2.04.132 Genetic Testing for Limb-Girdle Muscular Dystrophies
    Medical Policy MP 2.04.132 Genetic Testing for Limb-Girdle Muscular Dystrophies BCBSA Ref. Policy: 2.04.132 Related Policies Last Review: 05/27/2021 2.04.86 Genetic Testing for Duchenne and Becker Effective Date: 05/27/2021 Muscular Dystrophy Section: Medicine 2.04.105 Genetic Testing for Facioscapulohumeral Muscular Dystrophy 2.04.570 Genetic Counseling DISCLAIMER/INSTRUCTIONS FOR USE Medical policy provides general guidance for applying Blue Cross of Idaho benefit plans (for purposes of medical policy, the terms “benefit plan” and “member contract” are used interchangeably). Coverage decisions must reference the member specific benefit plan document. The terms of the member specific benefit plan document may be different than the standard benefit plan upon which this medical policy is based. If there is a conflict between a member specific benefit plan and the Blue Cross of Idaho’s standard benefit plan, the member specific benefit plan supersedes this medical policy. Any person applying this medical policy must identify member eligibility, the member specific benefit plan, and any related policies or guidelines prior to applying this medical policy, including the existence of any state or federal guidance that may be specific to a line of business. Blue Cross of Idaho medical policies are designed for informational purposes only and are not an authorization, explanation of benefits or a contract. Receipt of benefits is subject to satisfaction of all terms and conditions of the member specific benefit plan coverage. Blue Cross of Idaho reserves the sole discretionary right to modify all its policies and guidelines at any time.
    [Show full text]
  • Γ-Sarcoglycan Deficiency Increases Cell Contractility, Apoptosis And
    Research Article 1405 γ-Sarcoglycan deficiency increases cell contractility, apoptosis and MAPK pathway activation but does not affect adhesion Maureen A. Griffin1,2, Huisheng Feng1,3, Manorama Tewari1,2, Pedro Acosta1,3, Masataka Kawana1,3, H. Lee Sweeney1,3,4 and Dennis E. Discher1,2,4,* 1Pennsylvania Muscle Institute, University of Pennsylvania Medical Center, D-700 Richards Building, 3700 Hamilton Walk, Philadelphia, PA 19104-6083, USA 2Department of Chemical and Biomolecular Engineering, Towne Building, 220 South 33rd Street, University of Pennsylvania, Philadelphia, PA 19104-6393, USA 3Department of Physiology, University of Pennsylvania Medical Center, 3700 Hamilton Walk, Philadelphia, PA 19104-6085, USA 4Graduate Group in Cell and Molecular Biology, University of Pennsylvania Medical Center, 3620 Hamilton Walk, Philadelphia, PA 19104-6058, USA *Author for correspondence (e-mail: [email protected]) Accepted 10 January 2005 Journal of Cell Science 118, 1405-1416 Published by The Company of Biologists 2005 doi:10.1242/jcs.01717 Summary The functions of γ-sarcoglycan (γSG) in normal myotubes striations were more prominent in γSG-deficient myotubes are largely unknown, however γSG is known to assemble than in normal cells. An initial phosphoscreen of more than into a key membrane complex with dystroglycan and its 12 signaling proteins revealed a number of differences deficiency is one known cause of limb-girdle muscular between normal and γSG–/– muscle, both before and after dystrophy. Previous findings of apoptosis from γSG- stretching. MAPK-pathway proteins displayed the largest deficient mice are extended here to cell culture where changes in activation, although significant phosphorylation apoptosis is seen to increase more than tenfold in γSG- also appeared for other proteins linked to hypertension.
    [Show full text]
  • Rabbit Anti-DAZAP1/FITC Conjugated Antibody-SL14200R-FITC
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-DAZAP1/FITC Conjugated antibody SL14200R-FITC Product Name: Anti-DAZAP1/FITC Chinese Name: FITC标记的无精症缺失相关蛋白1抗体 DAZ associated protein 1; DAZ-associated protein 1; Dazap1; DAZP1_HUMAN; Alias: Deleted in azoospermia associated protein 1; Deleted in azoospermia-associated protein 1. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Chicken,Dog,Pig,Cow,Horse,Sheep, ICC=1:50-200IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 43kDa Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: KLH conjugated synthetic peptide derived from human DAZAP1 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01Mwww.sunlongbiotech.com TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. background: In mammals, the Y chromosome directs the development of the testes and plays an important role in spermatogenesis. A high percentage of infertile men have deletions that map to regions of the Y chromosome. The DAZ (deleted in azoospermia) gene Product Detail: cluster maps to the AZFc region of the Y chromosome and is deleted in many azoospermic and severely oligospermic men.
    [Show full text]
  • Beta Sarcoglycan (SGCB) (NM 000232) Human Untagged Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for SC120022 beta Sarcoglycan (SGCB) (NM_000232) Human Untagged Clone Product data: Product Type: Expression Plasmids Product Name: beta Sarcoglycan (SGCB) (NM_000232) Human Untagged Clone Tag: Tag Free Symbol: SGCB Synonyms: A3b; LGMD2E; LGMDR4; SGC Vector: pCMV6-XL5 E. coli Selection: Ampicillin (100 ug/mL) Cell Selection: None Fully Sequenced ORF: >NCBI ORF sequence for NM_000232, the custom clone sequence may differ by one or more nucleotides ATGGCGGCAGCGGCGGCGGCGGCTGCAGAACAGCAAAGTTCCAATGGTCCTGTAAAGAAGTCCATGCGTG AGAAGGCTGTTGAGAGAAGGAGTGTCAATAAAGAGCACAACAGTAACTTTAAAGCTGGATACATTCCGAT TGATGAAGATCGTCTCCACAAAACAGGGTTGAGAGGAAGAAAGGGCAATTTAGCCATCTGTGTGATTATC CTCTTGTTTATCCTGGCTGTCATCAATTTAATAATAACACTTGTTATTTGGGCCGTGATTCGCATTGGAC CAAATGGCTGTGATAGTATGGAGTTTCATGAAAGTGGCCTGCTTCGATTTAAGCAAGTATCTGACATGGG AGTGATCCACCCTCTTTATAAAAGCACAGTAGGAGGAAGGCGAAATGAAAATTTGGTCATCACTGGCAAC AACCAGCCTATTGTTTTTCAGCAAGGGACAACAAAGCTCAGTGTAGAAAACAACAAAACTTCTATTACAA GTGACATCGGCATGCAGTTTTTTGACCCGAGGACTCAAAATATCTTATTCAGCACAGACTATGAAACTCA TGAGTTTCATTTGCCAAGTGGAGTGAAAAGTTTGAATGTTCAAAAGGCATCTACTGAAAGGATTACCAGC AATGCTACCAGTGATTTAAATATAAAAGTTGATGGGCGTGCTATTGTGCGTGGAAATGAAGGTGTATTCA TTATGGGCAAAACCATTGAATTTCACATGGGTGGTAATATGGAGTTAAAGGCGGAAAACAGTATCATCCT AAATGGATCTGTGATGGTCAGCACCACCCGCCTACCCAGTTCCTCCAGTGGAGACCAGTTGGGTAGTGGT GACTGGGTACGCTACAAGCTCTGCATGTGTGCTGATGGGACGCTCTTCAAGGTGCAAGTAACCAGCCAGA
    [Show full text]
  • SGCE Rabbit Pab
    Leader in Biomolecular Solutions for Life Science SGCE Rabbit pAb Catalog No.: A5330 Basic Information Background Catalog No. This gene encodes the epsilon member of the sarcoglycan family. Sarcoglycans are A5330 transmembrane proteins that are components of the dystrophin-glycoprotein complex, which link the actin cytoskeleton to the extracellular matrix. Unlike other family Observed MW members which are predominantly expressed in striated muscle, the epsilon 55kDa sarcoglycan is more broadly expressed. Mutations in this gene are associated with myoclonus-dystonia syndrome. This gene is imprinted, with preferential expression from Calculated MW the paternal allele. Alternatively spliced transcript variants encoding different isoforms 49kDa/51kDa/52kDa have been found for this gene. A pseudogene associated with this gene is located on chromosome 2. Category Primary antibody Applications WB,IHC,IF Cross-Reactivity Human, Mouse Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 8910 O43556 IHC 1:50 - 1:200 Immunogen 1:50 - 1:200 IF Recombinant fusion protein containing a sequence corresponding to amino acids 1-317 of human SGCE (NP_003910.1). Synonyms SGCE;DYT11;ESG;epsilon-SG Contact Product Information www.abclonal.com Source Isotype Purification Rabbit IgG Affinity purification Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using SGCE antibody (A5330) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (RM00020).
    [Show full text]
  • Altered Ca2+ Handling and Oxidative Stress Underlie Mitochondrial Damage and Skeletal Muscle Dysfunction in Aging and Disease
    H OH metabolites OH Review Altered Ca2+ Handling and Oxidative Stress Underlie Mitochondrial Damage and Skeletal Muscle Dysfunction in Aging and Disease Antonio Michelucci 1,*, Chen Liang 2 , Feliciano Protasi 3 and Robert T. Dirksen 2 1 DNICS, Department of Neuroscience, Imaging, and Clinical Sciences, University G. d’Annunzio of Chieti-Pescara, I-66100 Chieti, Italy 2 Department of Pharmacology and Physiology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY 14642, USA; [email protected] (C.L.); [email protected] (R.T.D.) 3 CAST, Center for Advanced Studies and Technology, DMSI, Department of Medicine and Aging Sciences, University G. d’Annunzio of Chieti-Pescara, I-66100 Chieti, Italy; [email protected] * Correspondence: [email protected] Abstract: Skeletal muscle contraction relies on both high-fidelity calcium (Ca2+) signals and robust capacity for adenosine triphosphate (ATP) generation. Ca2+ release units (CRUs) are highly organized junctions between the terminal cisternae of the sarcoplasmic reticulum (SR) and the transverse tubule (T-tubule). CRUs provide the structural framework for rapid elevations in myoplasmic Ca2+ during excitation–contraction (EC) coupling, the process whereby depolarization of the T-tubule membrane triggers SR Ca2+ release through ryanodine receptor-1 (RyR1) channels. Under conditions of local Citation: Michelucci, A.; Liang, C.; or global depletion of SR Ca2+ stores, store-operated Ca2+ entry (SOCE) provides an additional 2+ Protasi, F.; Dirksen, R.T. Altered Ca source of Ca2+ that originates from the extracellular space. In addition to Ca2+, skeletal muscle also Handling and Oxidative Stress requires ATP to both produce force and to replenish SR Ca2+ stores.
    [Show full text]
  • Abstracts from the 50Th European Society of Human Genetics Conference: Electronic Posters
    European Journal of Human Genetics (2019) 26:820–1023 https://doi.org/10.1038/s41431-018-0248-6 ABSTRACT Abstracts from the 50th European Society of Human Genetics Conference: Electronic Posters Copenhagen, Denmark, May 27–30, 2017 Published online: 1 October 2018 © European Society of Human Genetics 2018 The ESHG 2017 marks the 50th Anniversary of the first ESHG Conference which took place in Copenhagen in 1967. Additional information about the event may be found on the conference website: https://2017.eshg.org/ Sponsorship: Publication of this supplement is sponsored by the European Society of Human Genetics. All authors were asked to address any potential bias in their abstract and to declare any competing financial interests. These disclosures are listed at the end of each abstract. Contributions of up to EUR 10 000 (ten thousand euros, or equivalent value in kind) per year per company are considered "modest". Contributions above EUR 10 000 per year are considered "significant". 1234567890();,: 1234567890();,: E-P01 Reproductive Genetics/Prenatal and fetal echocardiography. The molecular karyotyping Genetics revealed a gain in 8p11.22-p23.1 region with a size of 27.2 Mb containing 122 OMIM gene and a loss in 8p23.1- E-P01.02 p23.3 region with a size of 6.8 Mb containing 15 OMIM Prenatal diagnosis in a case of 8p inverted gene. The findings were correlated with 8p inverted dupli- duplication deletion syndrome cation deletion syndrome. Conclusion: Our study empha- sizes the importance of using additional molecular O¨. Kırbıyık, K. M. Erdog˘an, O¨.O¨zer Kaya, B. O¨zyılmaz, cytogenetic methods in clinical follow-up of complex Y.
    [Show full text]
  • 2021 Code Changes Reference Guide
    Boston University Medical Group 2021 CPT Code Changes Reference Guide Page 1 of 51 Background Current Procedural Terminology (CPT) was created by the American Medical Association (AMA) in 1966. It is designed to be a means of effective and dependable communication among physicians, patients, and third-party payers. CPT provides a uniform coding scheme that accurately describes medical, surgical, and diagnostic services. CPT is used for public and private reimbursement systems; development of guidelines for medical care review; as a basis for local, regional, and national utilization comparisons; and medical education and research. CPT Category I codes describe procedures and services that are consistent with contemporary medical practice. Category I codes are five-digit numeric codes. CPT Category II codes facilitate data collection for certain services and test results that contribute to positive health outcomes and quality patient care. These codes are optional and used for performance management. They are alphanumeric five-digit codes with the alpha character F in the last position. CPT Category III codes represent emerging technologies. They are alphanumeric five-digit codes with the alpha character T in the last position. The CPT Editorial Panel, appointed by the AMA Board of Trustees, is responsible for maintaining and updating the CPT code set. Purpose The AMA makes annual updates to the CPT code set, effective January 1. These updates include deleted codes, revised codes, and new codes. It’s important for providers to understand the code changes and the impact those changes will have to systems, workflow, reimbursement, and RVUs. This document is meant to assist you with this by providing a summary of the changes; a detailed breakdown of this year’s CPT changes by specialty, and HCPCS Updates for your reference.
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • Further Evidence for the Organisation of the Four Sarcoglycans Proteins Within the Dystrophin–Glycoprotein Complex
    European Journal of Human Genetics (1999) 7, 251–254 © 1999 Stockton Press All rights reserved 1018–4813/99 $12.00 t http://www.stockton-press.co.uk/ejhg SHORT REPORT Further evidence for the organisation of the four sarcoglycans proteins within the dystrophin–glycoprotein complex M Vainzof1,2, ES Moreira2, G Ferraz3, MR Passos-Bueno2, SK Marie1 and M Zatz2 1Departamento de Neurologia, FMUSP, S˜ao Paulo 2Departamento de Biologia, IB-USP, S˜ao Paulo 3Departamento de Gen´etica, UFPE, Recife, PE, Brazil Based on the pattern of distribution of the SG proteins in patients with LGMD2C and 2D, and on the observed decreased abundance of dystrophin through WB in some sarcoglycans (SG) patients, we have recently suggested that α, â and δ subunits of sarcoglycan complex might be more closely associated and that γ-SG might interact more directly with dystrophin. Two additional SG patients here reported give further support to these suggestions: an LGMD2F patient showed patchy labelling for γ-SG, despite the lack of staining of the other three SG proteins; an LGMD2C boy showed deficiency in dystrophin by means of WB and IF, comparable with an DMD manifesting carrier. These two patients represent further evidence of a closer relation of α, â and δ-SG than of γ-SG and of the possible association of γ-SG with dystrophin. In addition the LGMD2C patient illustrates the potential risk of misdiagnosis using only dystrophin analysis, in cases with no positive family history, or when DNA analysis is not informative. Keywords: sarcoglycans; muscular dystrophy;
    [Show full text]